CLS12311 / Cellerys, Novartis - LARVOL DELTA

RED4MS: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - P1 | N=11 | Active, not recruiting | Sponsor: Cellerys AG | Recruiting ➔ Active, not recruiting | Phase classification: P1/2 ➔ P1 | N=135 ➔ 11 | Trial completion date: Mar 2027 ➔ Dec 2025 | Trial primary completion date: Aug 2026 ➔ Dec 2025

Enrollment change • Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • CNS Disorders • Multiple Sclerosis

Induction of antigen-specific immune tolerance with autologous peptide-coupled red blood cells – the RED4MS trial (ECTRIMS 2024) - "RED4MS trial will provide proof-of-concept on efficacy of CLS12311 and proof-of-mechanism data on an innovative tolerization therapy in RRMS patients."

CNS Disorders • Immunology • Inflammation • Multiple Sclerosis

RED4MS: Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis (clinicaltrials.gov) - P1/2 | N=135 | Recruiting | Sponsor: Cellerys AG | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis